Abstract
Targeting B-cell maturation antigen with chimeric antigen receptor (CAR) T-cells is a new standard of care in relapsed/refractory multiple myeloma (RRMM). However, long-term data have currently remained sparse. In a recent study published in the Journal for ImmunoTherapy of Cancer by Jin et al, authors reported on a large cohort of 141 patients with a median follow-up of 20.2 months. They found an overall response rate of 90.1% with 48.2% achieving a complete response. The median progression-free survival was 15.2 months, and the 4-year overall survival rate was 63.2%. In the current article, we summarize the published long-term data from clinically approved and investigational CAR T-cells for RRMM.